BioSpace News Archive

sterna biologicals GmbH & Co. KG (sterna) announced that the Company has recently appointed Dr. Marion Wencker as consulting Chief Medical Officer and Dr. Thomas Klaue as consulting Chief Financial Officer.

The early-stage biotech company, previously named FLX Bio, plans to raise up to $86 million with the IPO. It plans to trade on the Nasdaq under the ticker symbol RAPT.

Roche and Spark initially agreed to the acquisition in February of this year. The deal has had mutiple delays due to regulatory scrutiny.

Evotec SE announced the formation of Breakpoint Therapeutics GmbH, a spin-off company focusing on the development of Evotec’s DNA damage response (“DDR”) portfolio, comprising discovery-stage assets and drug targets that promise broad therapeutic application in a variety of cancers.

Company Signs Top Ten Global Pharmaceutical Company as New Client and Expands Relationship with Existing Biotechnology Company Customer

“Non-muscle invasive bladder cancer is a highly prevalent illness that requires an intrusive and often lengthy treatment plan,” stated Hardev Pandha, lead investigator and Professor of Medical Oncology at the University of Surrey, reported Forbes. “Current treatment is ineffective and toxic in a proportion of patients and there is an urgent need for new therapies.”

SkinBioTherapeutics plc, a life sciences company focused on skin health, announces changes to its Board and executive team and provides a business update.

Da Volterra, a clinical-stage biopharmaceutical company developing new therapeutics to protect the intestinal microbiota, announced the completion of patient recruitment for its Phase 2 trial ‘SHIELD’ evaluating DAV132 in patients receiving antibiotics.

Longer than expected PFS for murlentamab when combined with FTD/TPI, particularly in patients with medium/high AMHRII expression, along with immune cascade activation in the tumor micro-environment

Prestige BioPharma and Pharmapark LLC announced that the two companies have entered into a binding agreement for the exclusive partnership and supply for the commercialization of Prestige BioPharma´s Trastuzumab biosimilar in the Russian Federation.